Skip to content

Neuroplasticity: all studies

Page 81 of 178: studies 801 to 810 of 1,772, newest first. Back to the neuroplasticity overview

Research

Inhibitor-Free Variant of the Cheung Regimen: Successful Adjunctive Therapy in Long-Standing Hypochondriasis With Prominent Somatic Features

Cureus March 17, 2026 Ngo Cheung

Hypochondriacal obsessive-compulsive disorder (OCD) combines intrusive health anxieties with compulsive reassurance seeking and often resists high-dose selective serotonin reuptake inhibitors and cognitive-behavioural therapy. Interest has shifted toward glutamatergic agents that mimic ketamine's rapid synaptic effects. A 34-year-old woman endured two years of recurrent fear of serious...

Yoga in Managing Psychiatric Disorders

International Journal of Advanced Research in Science, Communication and Technology March 17, 2026 Gajanan Tekale Pornima Gautam Surwade, Dr. Shivshankar D. Mahske

Yoga, an ancient mind-body practice originating from India, has gained recognition as a complementary intervention for managing psychiatric disorders. Derived from the Sanskrit term “Yuj,” meaning “to unite,” yoga integrates physical postures (asanas), breath regulation (pranayama), and meditation (dhyana) to promote harmony between body, mind, and spirit. Unlike conventional exercise, yoga...

Holotropic States and Developmental Trauma: A Trauma-Informed, Phase-Oriented Framework

March 17, 2026 Lindsey T. Owens preprint

Discussions around the diagnosis and treatment of developmental trauma continue to evolve, yet a growing body of literature highlights its profound impact on physical, emotional, cognitive, and relational functioning. Developmental trauma often involves coping strategies adapted in response to chronic early-life adversity, including physiological and emotional dysregulation, attachment...

DOI: 10.31234/osf.io/rc39w_v1 (opens in new tab) Coping psychology Perception Emotional regulation Clinical practice +3

Decoding the molecular network communication mechanism of ketamine's antidepressant effects.

Psychopharmacology March 16, 2026 Ye Li, Qilong Cheng, Guoxin Lin et al.

RATIONALE: Major Depressive Disorder (MDD) is a global public health burden, with traditional monoaminergic antidepressants facing critical limitations including slow onset, adverse side effects, and high rates of treatment resistance (TRD). Ketamine, a rapid-acting agent with sustained antidepressant effects, has revolutionized depression treatment paradigms but challenges conventional...

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application

Frontiers in Pharmacology March 16, 2026 Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino

psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...

DOI: 10.3389/fphar.2026.1816812 (opens in new tab) Addiction Neurotoxicity Mechanism biology Recreational use +7

A respite in the chaos. Meditation as a response to the brainrot.

International journal of education & well-being. March 15, 2026 Joanna Betlejewska

This article addresses the phenomenon of brain rot, a growing global concern arising from the excessive consumption of low-quality virtual stimuli. Brain rot is associated with persistent anxiety, reduced attention and concentration, mood disturbances, and loss of self-esteem. In the long term, it may contribute to mental and emotional disorders, behavioral addictions, and significant...

Facilitating Mindfulness Training with Ultrasonic Neuromodulation

bioRxiv March 13, 2026 Brian Lord, Erica N. Lord, Jessica N. Schachtner et al. preprint

Systematic focus training is increasingly recognized for its therapeutic benefits, with equanimity, the ability to maintain an open and accepting attitude towards all experience, identified as a critical mechanism for improving well-being. Physiologically, experienced meditators demonstrate reduced activity in the posterior cingulate cortex (PCC), a hub of the default mode network (DMN), and...

The renaissance of research on psychedelics in child and adolescent psychopharmacology

Child and Adolescent Psychiatry and Mental Health March 13, 2026 Marc-Antoine Crocq, Philippe Auby

Aims The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. Methods We reviewed recent literature, regulatory documents, and clinical trial...

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review

Schizophrenia Research March 13, 2026 Michel Sabé, Paul Grof, Nathan Sackett et al. 1 citation

Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....

Measuring the psychoactive effects of ketamine in alcohol use disorder: When assessment shapes experience

Addiction March 11, 2026 Christina Mcanulty, Nicolas Garel

Bloy et al. [1] provide an important and methodologically rigorous secondary analysis of the Ketamine for the reduction of Alcoholic Relapse (KARE) trial, examining whether acute psychoactive effects mediate the therapeutic impact of ketamine in alcohol use disorder (AUD). Their finding that dissociative and perceptual effects did not mediate abstinence outcomes is clinically relevant, and...

DOI: 10.1111/add.70396 (opens in new tab) Ketamine Alcohol Psychoactive drug Medline +1